KEY PRODUCTS
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
01 1Bachem AG
01 1ETOMIDATE
01 1Switzerland
01 1Active
01 1Complete
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
GDUFA
DMF Review : Complete
Rev. Date : 2014-10-16
Pay. Date : 2014-10-14
DMF Number : 20234
Submission : 2007-01-29
Status : Active
Type : II
20
Bachem Sa, based in Switzerland, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
One of their notable products is ETOMIDATE, with a corresponding US DMF Number 20234.
Remarkably, this DMF maintains an Active status since its submission on January 29, 2007, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of October 16, 2014, and payment made on October 14, 2014, indicating their dedication to facilitating drug approvals, Categorized as Type II
